MARKET

CLRBZ

CLRBZ

CELLECTAR BIOSC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2400
+0.0199
+9.04%
Closed 16:00 12/03 EST
OPEN
0.2699
PREV CLOSE
0.2201
HIGH
0.2699
LOW
0.1801
VOLUME
141.84K
TURNOVER
--
52 WEEK HIGH
1.540
52 WEEK LOW
0.0400
MARKET CAP
--
P/E (TTM)
-0.2015
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
No Data
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLRBZ. Analyze the recent business situations of CELLECTAR BIOSC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Independent Director
Douglas Swirsky
President/Chief Executive Officer/Director
James Caruso
Chief Financial Officer/Vice President
Dov Elefant
Vice President
John Friend
Other
Jarrod Longcor
Independent Director
Frederick Driscoll
Independent Director
Stephen Hill
Independent Director
Stefan Loren
Independent Director
John Neis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLRBZ
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRBZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRBZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRBZ stock methods without spending real money on the virtual paper trading platform.